≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback

Benign neoplasm: Parathyroid gland

DOID EFO Endpoint Browser PheWeb

CD2_BENIGN_PARATHYROID

Endpoint definition

↥

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D35.1&
  • Hospital discharge: ICD-9 — 2271
  • Cause of death: ICD-10 — D35.1&
  • Cause of death: ICD-9 — 2271

2 out of 7 registries used, show all original rules.

365

4. Check minimum number of events

None

365

5. Include endpoints

None

365

6. Filter based on genotype QC (FinnGen only)

365

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D35
Name in latin
Neoplasma benignum glandulae parathyreoideae

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2464 1832 617
Only index persons 2183 1635 548
Unadjusted period prevalence (%)
Whole population 0.04 0.05 0.02
Only index persons 0.05 0.06 0.02
Median age at first event (years)
Whole population 63.70 64.32 61.99
Only index persons 62.91 63.38 61.51

-FinnGen-

Key figures

All Female Male
Number of individuals 365 259 106
Unadjusted period prevalence (%) 0.08 0.09 0.05
Median age at first event (years) 60.83 60.15 62.51

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
330
Matched controls
3299
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D35.1
ICD-10 Finland
Benign neoplasm: Parathyroid gland
4503599627370496.0
323.0
301
*
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
240.1
181.2
173
15
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
88.0
133.8
145
29
E21.0
ICD-10 Finland
Primary hyperparathyroidism
74.9
89.7
100
19
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
65.5
70.2
80
16
BBA20
NOMESCO Finland
Exploration of parathyroid gland
101.2
40.9
44
5
BBA40
NOMESCO Finland
Subtotal parathyroidectomy
59.3
32.0
37
7
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.0
31.8
205
951
E83.50
ICD-10 Finland
Hypercalcemia
31.0
31.0
41
15
E21.2
ICD-10 Finland
Other hyperparathyroidism
64.9
30.8
35
6
2271A
ICD-9 Finland
Benign neoplasm of other endocrine glands and related structures, Parathyroid gland
+∞
27.5
26
*
BAA40
NOMESCO Finland
Unilateral lobectomy of thyroid gland
15.5
24.3
40
29
2522
FHL
Removal of parathyroidism or multiple parathyroidism (including removal of adenoma or total removal)
+∞
24.3
23
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.0
18.0
134
607
321
Kela drug reimbursment
Paricalcitol and cinacalcet
39.1
17.8
22
6
H05BX01
ATC
cinacalcet; oral
39.1
17.8
22
6
A11CC03
ATC
alfacalcidol; systemic
11.3
17.1
32
31
E21
ICD-10 Finland
Hyperparathyroidism and other disorders of parathyroid gland
89.4
15.7
17
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
5.3
15.2
48
103
BB1BQ
NOMESCO Finland
Extensive scintigraphy of parathyroid gland, 2 isotopes, SPECT and low-dose CT
55.8
13.9
16
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
22.3
13.5
19
9
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
4.1
12.9
52
143
N20.0
ICD-10 Finland
Calculus of kidney
9.9
12.2
24
26
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
9.5
12.0
24
27
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
48.5
12.0
14
*
N20.9
ICD-10 Finland
Urinary calculus, unspecified
10.2
11.9
23
24
2520A
ICD-9 Finland
Disorders of parathyroid gland, Hyperparathyroidism
+∞
11.5
11
*
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
11.1
10.9
20
19
KAT00
NOMESCO Finland
Extracorporeal shock wave lithotripsy of pelvis of kidney
22.4
10.8
15
7
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
24.3
10.3
14
6
KH1AA
NOMESCO Finland
Urinary tract X-ray examination without contrast
15.6
9.6
15
10
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
7.3
9.5
22
32
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
6.6
9.3
23
37
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
6.7
8.9
22
35
E23.00
ICD-10 Finland
Panhypopituitarism
51.4
8.7
10
*
106
Kela drug reimbursment
Hypoparathyroidism
28.3
8.5
11
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
92.3
8.5
9
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
7.4
8.4
19
27
N18.8
ICD-10 Finland
Other chronic renal failure
6.9
8.0
19
29
CA1TM
NOMESCO Finland
Calculation of intraocular lens power
8.1
8.0
17
22
I10
ICD-10 Finland
Essential (primary) hypertension
2.0
7.9
218
1637
A12AA04
ATC
calcium carbonate; oral
8.8
7.9
16
19
E04.9
ICD-10 Finland
Nontoxic goitre, unspecified
5.8
7.8
21
38
V03AE02
ATC
sevelamer; oral
46.1
7.7
9
*
KH1AD
NOMESCO Finland
CT of urinary organs
5.5
7.5
21
40
E21.5
ICD-10 Finland
Disorder of parathyroid gland, unspecified
81.9
7.4
8
*
M04AA01
ATC
allopurinol; systemic
2.7
7.4
53
222
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
16.2
7.3
11
7
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.1
6.7
85
466
E89.2
ICD-10 Finland
Postprocedural hypoparathyroidism
23.1
6.7
9
*
H02AB09
ATC
hydrocortisone; systemic
8.1
6.7
14
18
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
12.6
6.6
11
9
H03AA01
ATC
levothyroxine sodium; systemic
2.0
6.6
96
557
KA1AE
NOMESCO Finland
Kidney ultrasound examination
5.9
6.5
17
30
N20.1
ICD-10 Finland
Calculus of ureter
4.6
6.5
21
48
TJA35
NOMESCO Finland
Removal of peritoneal dialysis catheter
71.2
6.4
7
*
TDW99
NOMESCO Finland
Other minor procedure in surgery of ear, nose and larynx
4.5
6.4
21
49
A11CC02
ATC
dihydrotachysterol; oral
27.2
6.3
8
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.3
6.2
30
98
KBE12
NOMESCO Finland
Transluminal endoscopic extraction of calculus of ureter
12.8
6.1
10
8
C08CA01
ATC
amlodipine; oral
1.8
6.1
135
910
WX199
NOMESCO Finland
Other local analgesia
4.9
6.0
18
38

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
184
252
13.71
141.42
7.0
3.2
119.2
75.7
ng/l
3.43
168
224
155
372
6.50
66.54
10.7
4.5
1.0
1.0
mmol/l
2.78
144
347
122
318
5.26
45.80
16.3
4.1
—
—
—
0
0
300
1618
5.80
42.31
19.5
6.1
1.3
1.2
mmol/l
14.26
277
1383
261
1335
4.35
37.61
4.2
2.2
78.9
79.9
nmol/l
0.25
247
1171
212
1124
3.11
25.02
4.1
3.2
2.4
2.4
mmol/l
6.93
195
976
135
631
2.81
18.89
3.2
3.1
2.5
2.5
mmol/l
4.12
125
553
152
761
2.71
18.53
3.0
2.2
—
—
—
0
0
35
69
5.50
17.31
3.5
2.8
7.5
7.8
kpa
0.40
29
61
224
1386
2.60
17.25
8.7
4.2
36.0
35.5
g/l
0.98
213
1286
178
997
2.53
16.83
2.9
2.3
—
—
—
0
0
33
64
5.57
16.60
5.0
2.6
—
—
—
0
0
228
1475
2.45
15.17
5.1
4.0
—
—
—
0
0
96
422
2.73
14.65
18.8
22.3
1.4
1.2
inr
0.97
61
62
28
53
5.64
14.42
3.5
2.8
—
—
—
0
0
36
87
4.48
14.03
4.2
2.6
24.6
25.1
mmol/l
0.27
24
74
56
193
3.25
13.13
4.6
3.5
5.2
5.1
kpa
0.07
49
179
54
189
3.18
12.32
4.2
3.5
7.4
7.4
ph
—
5
23
118
620
2.33
12.04
4.2
3.9
113.9
293.7
ng/l
0.94
85
497
199
1322
2.11
11.03
2.3
2.1
—
—
—
0
0
121
669
2.21
10.75
5.6
2.4
3.7
6.0
e6/l
1.09
112
589
216
1491
2.10
10.68
11.5
5.3
1.3
1.2
mmol/l
10.38
205
1341
246
1786
2.16
10.60
8.4
9.0
4.1
4.1
e9/l
0.06
217
1562
83
401
2.38
10.07
1.3
1.3
—
—
—
0
0
17
28
6.32
10.01
1.3
1.6
—
—
—
0
0
21
43
5.12
9.91
1.5
1.2
—
—
—
0
0
309
2498
2.54
9.76
11.1
7.4
85.7
78.4
u/l
0.56
296
2323
20
40
5.23
9.68
1.5
1.2
—
—
nmol/l
—
0
0
205
1420
2.01
9.67
5.4
5.6
3.2
2.8
%
1.55
194
1315
203
1425
1.96
8.96
5.7
5.9
8.9
8.5
%
0.63
193
1329
60
263
2.53
8.93
3.3
3.0
241.5
220.1
ng/l
0.12
55
242
197
1370
1.95
8.93
5.5
5.6
0.7
0.7
%
0.39
187
1268
204
1448
1.93
8.57
5.6
5.8
27.0
27.6
%
0.31
194
1339
109
626
2.06
8.48
2.0
1.7
967.1
1222.5
nmol/l
2.66
92
475
152
983
1.94
8.41
3.9
4.0
—
—
—
0
0
132
815
1.97
8.37
5.3
2.6
3977.0
7070.7
umol/l
0.35
123
695
217
1582
1.92
8.30
5.6
5.7
0.2
0.2
e9/l
0.81
186
1390
62
289
2.38
8.05
13.4
3.2
—
—
—
0
0
154
1015
1.89
7.94
4.9
3.1
—
—
—
0
0
150
985
1.89
7.79
5.1
3.1
7.3
7.0
mmol/l
0.27
135
801
148
968
1.89
7.78
5.8
3.1
95.2
108.1
e6/l
0.05
129
726
152
1004
1.88
7.74
8.8
3.7
7.4
7.4
ph
1.59
25
178
273
2175
2.01
7.72
7.0
4.4
—
—
—
0
0
37
136
2.91
7.71
3.8
3.5
—
—
—
0
0
60
282
2.35
7.64
13.6
3.1
2.1
2.5
mmol/l
0.42
50
226
209
1533
1.85
7.55
5.5
5.5
0.0
0.0
e9/l
0.33
179
1320
55
255
2.36
7.21
7.7
2.8
67.8
70.6
e9/l
0.34
47
202
186
1331
1.81
7.15
2.3
2.0
102.3
96.7
pmol/l
0.60
107
653
197
1438
1.80
7.05
5.5
5.5
57.9
57.6
%
0.16
187
1339
164
1136
1.81
6.98
5.9
3.6
70.5
90.0
e6/l
0.34
131
794
241
1878
1.83
6.85
7.3
4.5
6.5
6.7
mmol/l
1.48
234
1758
13
24
5.58
6.82
1.2
1.2
—
—
—
0
0
121
771
1.85
6.71
3.7
2.1
2.5
3.3
mg/l
4.54
110
663
286
2367
1.96
6.56
7.0
4.2
15.1
12.7
mm/h
1.63
274
2155
207
1555
1.77
6.52
5.5
5.6
1.7
2.0
e9/l
1.73
175
1377
111
695
1.86
6.47
1.7
1.6
1.0
1.2
mg/l
0.30
90
548
52
247
2.29
6.43
9.9
6.9
—
—
—
0
0
202
1522
1.73
6.16
5.4
5.5
0.6
0.6
e9/l
0.37
172
1310
11
19
5.94
6.14
1.0
1.1
—
—
—
0
0
71
404
1.94
5.47
1.5
1.3
728.0
481.2
titre
0.32
15
97
289
3206
0.53
5.41
19.0
13.7
—
—
—
0
0
327
2902
2.22
5.29
6.3
5.0
1.8
2.0
mu/l
0.88
308
2622
288
2449
1.83
5.29
5.2
4.1
14.3
14.9
pmol/l
3.48
271
2202
137
960
1.68
5.23
5.3
3.2
61.6
119.1
mg/l
0.37
106
581
52
272
2.06
5.05
2.1
2.7
67.6
66.4
g/l
0.49
42
249
143
1023
1.65
4.99
4.4
2.3
63.8
56.3
u/l
0.52
135
939
123
856
1.66
4.73
4.5
3.9
—
—
—
0
0
14
38
3.79
4.69
1.3
1.2
296.2
382.5
pmol/l
—
9
33
46
238
2.07
4.60
2.1
2.4
—
—
—
0
0
92
597
1.72
4.58
1.3
1.4
2.2
2.5
g/l
0.76
59
335
139
1010
1.61
4.45
6.0
4.1
12.3
7.8
mg/mmol
0.79
102
595
26
112
2.42
4.02
4.3
2.9
0.3
0.2
g/l
0.85
16
36
27
119
2.37
3.98
2.1
2.8
—
—
—
0
0
36
180
2.11
3.95
1.1
1.3
—
34.0
—
0
11
135
1003
1.55
3.81
2.3
2.0
241.9
183.3
u/l
0.24
124
939
167
1302
1.52
3.76
5.0
2.7
148.1
127.9
ug/l
0.57
160
1184
31
151
2.15
3.64
1.2
1.2
—
—
—
0
0
15
51
3.02
3.61
2.5
3.3
1.2
0.9
%
—
6
41
96
669
1.59
3.54
3.8
4.6
—
—
—
0
0
82
552
1.63
3.48
1.3
1.3
9.1
10.9
u/ml
0.09
32
212
13
42
3.17
3.40
1.2
1.1
—
—
—
0
0
7
10
7.11
3.38
31.7
35.3
98.4
93.1
ug/l
—
7
10
107
778
1.53
3.25
1.4
1.3
—
—
—
0
0
208
1736
1.46
3.14
6.6
6.0
12.1
11.1
umol/l
0.42
200
1639
18
74
2.51
3.10
2.1
4.7
—
—
—
0
0
333
3092
1.88
2.98
24.6
14.4
26.2
22.8
mg/l
1.11
288
2445
82
573
1.56
2.96
1.3
1.3
60.4
39.6
iu/ml
0.30
20
191
18
76
2.44
2.94
1.2
1.9
—
—
—
0
0
8
18
4.52
2.81
2.1
2.2
—
—
—
0
0
37
215
1.80
2.68
3.1
2.9
—
—
—
0
0
7
16
4.44
2.48
5.0
4.8
—
—
—
0
0
79
1045
0.69
2.26
2.7
3.1
—
—
—
0
0
5
9
5.61
2.22
1.4
1.3
149.4
119.6
iu/ml
—
5
9
12
48
2.55
2.21
2.9
1.2
—
—
—
0
0
11
42
2.67
2.20
1.3
1.1
327.3
269.8
u/ml
—
6
21
7
19
3.73
2.16
1.1
1.7
—
—
—
0
0
100
775
1.40
2.10
1.6
1.5
19.5
22.1
nmol/l
0.98
85
649
9
31
2.95
2.08
1.1
1.2
—
—
—
0
0
5
10
5.05
2.07
1.2
1.7
—
—
—
0
0
248
2711
0.73
1.98
19.7
15.4
39.9
39.5
%
0.32
169
1885
110
884
1.35
1.83
4.9
3.0
0.1
0.5
e6/l
3.92
78
648
343
3287
1.72
1.70
28.8
17.4
94.4
76.0
umol/l
4.06
343
3287
6
19
3.19
1.67
1.0
1.4
—
—
—
0
0
44
306
1.50
1.64
1.3
1.4
—
—
—
0
0
12
56
2.18
1.63
1.2
1.2
—
—
—
0
0
325
3083
1.49
1.61
4.9
4.7
4.7
4.7
mmol/l
0.01
312
2827
331
3153
1.53
1.59
5.4
5.3
2.8
2.8
mmol/l
0.07
314
2877
51
368
1.45
1.59
2.8
1.6
—
—
—
0
0
6
20
3.03
1.58
3.0
1.5
11.8
10.0
%
—
6
20
18
100
1.84
1.56
1.0
1.1
—
—
—
0
0
19
108
1.80
1.54
1.1
1.3
—
2.8
—
0
10
5
15
3.36
1.53
1.4
1.1
—
—
—
0
0
122
1019
1.30
1.52
5.6
5.4
—
—
—
0
0
6
21
2.89
1.51
2.0
2.6
—
—
—
0
0
79
621
1.35
1.50
3.6
2.7
505.2
541.1
mosm/kgh2o
1.05
70
516
36
246
1.51
1.47
2.9
4.3
0.0
0.2
%
2.91
14
78
18
103
1.79
1.43
1.2
2.0
37.8
37.3
g/l
—
10
92
322
3063
1.44
1.42
4.9
4.6
1.5
1.5
mmol/l
2.10
307
2794
11
53
2.11
1.40
1.2
1.5
—
—
—
0
0
27
176
1.58
1.36
1.3
1.2
—
—
—
0
0
9
44
2.07
1.27
1.3
1.3
—
—
—
0
0
37
264
1.45
1.25
3.0
4.2
0.8
1.0
%
0.24
15
86
8
37
2.19
1.22
1.0
1.1
—
—
—
0
0
5
19
2.65
1.22
1.0
5.0
—
—
—
0
0
310
2948
1.34
1.21
7.6
6.1
40.1
40.2
mmol/mol
0.07
291
2721
24
157
1.57
1.21
3.7
8.3
—
—
—
0
0
12
64
1.90
1.19
6.2
3.1
—
—
—
0
0
89
737
1.27
1.16
5.5
5.2
2.1
3.0
ug/l
0.81
79
652
321
3073
1.37
1.16
5.5
4.8
6.0
6.0
mmol/l
0.20
303
2785
14
80
1.78
1.14
1.8
1.6
17440.6
25877.8
e6/l
—
9
56
14
82
1.74
1.06
3.6
2.3
2.1
1.6
mg/l
1.33
14
72
50
388
1.33
1.05
1.6
1.3
—
—
—
0
0
100
851
1.24
1.04
4.3
2.9
—
—
—
0
0
5
22
2.29
1.03
3.0
2.2
—
—
—
0
0
7
34
2.08
1.03
1.0
1.1
—
—
—
0
0
82
683
1.26
1.02
1.2
1.2
0.8
1.1
u/ml
0.45
17
180
11
62
1.80
0.95
1.5
1.6
—
—
—
0
0
340
3303
1.43
0.94
14.6
10.8
24.9
24.8
u/l
0.02
332
3174
13
78
1.69
0.92
1.2
1.2
—
—
—
0
0
6
30
2.02
0.87
1.3
1.9
—
—
—
0
0
308
2958
1.26
0.87
4.6
4.2
1.4
1.3
mmol/l
3.19
289
2685
74
871
0.81
0.85
5.8
4.1
0.0
0.0
estimate
0.00
25
283
6
32
1.89
0.82
1.2
1.2
—
—
—
0
0
0
28
0.00
0.76
0.0
2.3
—
—
—
0
0
56
463
1.25
0.76
2.7
1.9
—
—
—
0
0
55
454
1.25
0.76
1.2
1.2
—
—
—
0
0
45
365
1.27
0.72
3.7
4.3
6.4
18.7
ug/l
0.54
39
304
21
152
1.40
0.71
2.2
1.5
—
—
—
0
0
80
701
1.18
0.62
1.9
1.7
633.5
461.7
pmol/l
0.41
72
571
34
272
1.28
0.62
3.8
5.8
1.0
1.3
mmol/l
2.08
34
261
8
50
1.61
0.61
1.3
1.5
—
—
—
0
0
8
50
1.61
0.61
1.1
1.3
—
—
—
0
0
5
30
1.68
0.61
1.0
1.1
—
—
—
0
0
5
30
1.68
0.61
1.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
38
310
1.25
0.60
2.1
1.4
—
—
—
0
0
0
22
0.00
0.59
0.0
1.6
—
—
—
0
0
0
23
0.00
0.58
0.0
3.0
—
—
—
0
0
23
176
1.33
0.58
2.4
2.6
—
—
—
0
0
44
368
1.22
0.56
1.3
1.3
—
—
—
0
0
6
37
1.63
0.56
1.3
1.3
—
—
—
0
0
117
1277
0.88
0.54
3.9
3.8
45.1
37.0
ng/l
0.18
86
926
9
62
1.46
0.53
2.6
2.4
—
—
—
0
0
43
364
1.21
0.50
3.3
6.7
12.6
12.2
kpa
0.24
43
350
43
364
1.21
0.50
1.8
2.1
79.7
121.9
ug/g
1.14
35
291
43
364
1.21
0.50
3.3
6.7
5.3
5.1
kpa
0.84
43
350
215
2253
0.89
0.50
3.7
4.0
—
—
—
0
0
15
110
1.38
0.49
1.6
1.7
—
—
—
0
0
7
108
0.64
0.49
3.4
3.8
4.1
3.9
mmol/l
—
7
97
13
94
1.40
0.46
1.5
1.4
312.6
298.5
ug/g
—
7
54
5
31
1.62
0.43
1.0
1.2
—
—
—
0
0
16
122
1.33
0.43
1.1
1.0
—
—
—
0
0
28
231
1.23
0.42
1.1
1.2
—
—
—
0
0
8
57
1.41
0.42
2.0
1.7
34.1
31.7
umol/l
—
8
44
0
17
0.00
0.40
0.0
1.4
—
—
—
0
0
38
326
1.18
0.40
3.4
6.9
96.6
95.7
%
1.07
38
314
5
37
1.36
0.37
1.0
1.2
—
—
—
0
0
81
883
0.89
0.37
1.6
1.6
1.5
1.3
mmol/l
1.48
72
734
6
41
1.47
0.36
1.8
3.6
—
—
—
0
0
6
41
1.47
0.36
1.0
1.1
—
—
—
0
0
6
46
1.31
0.33
2.5
3.4
—
—
—
0
0
6
47
1.28
0.32
1.7
1.2
—
—
—
0
0
85
787
1.10
0.31
8.6
6.5
—
—
—
0
0
31
268
1.17
0.31
2.2
1.4
—
—
—
0
0
7
97
0.72
0.31
1.9
1.3
—
—
—
0
0
41
363
1.15
0.31
3.3
6.8
0.8
1.4
mmol/l
0.62
30
291
11
84
1.32
0.30
1.0
1.1
—
—
—
0
0
48
431
1.13
0.30
3.1
3.1
0.8
0.7
ug/l
0.03
34
290
28
241
1.18
0.30
1.3
1.4
—
—
—
0
0
65
706
0.90
0.28
5.9
4.4
1.0
1.0
kg/l
0.00
22
94
13
105
1.25
0.25
1.3
1.6
—
—
—
0
0
39
351
1.12
0.24
2.5
1.5
—
—
—
0
0
22
253
0.86
0.23
8.3
3.8
—
—
—
0
0
14
168
0.83
0.23
3.4
3.9
—
—
—
0
0
5
40
1.25
0.22
1.0
1.9
0.5
0.9
g/l
—
5
35
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
2.1
—
0
10
0
12
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
108.4
—
0
7
0
13
0.00
0.21
0.0
5.5
—
41.5
—
0
13
22
193
1.15
0.20
1.7
3.0
13.3
46.2
u/ml
1.77
22
187
6
50
1.20
0.20
3.2
1.5
70.0
60.2
%
—
6
50
7
60
1.17
0.18
1.4
1.3
85.0
64.4
mmol/l
—
7
50
135
1397
0.95
0.17
10.9
9.6
0.0
0.0
e9/l
0.62
101
1149
18
205
0.87
0.17
1.3
1.3
—
—
—
0
0
7
62
1.13
0.17
1.1
1.2
3.4
3.8
mmol/l
—
7
57
16
139
1.16
0.16
2.7
1.9
—
—
—
0
0
8
70
1.15
0.16
1.3
1.2
457.3
538.4
mg/l
—
8
65
161
1565
1.05
0.16
4.7
3.9
0.0
0.0
estimate
0.00
26
292
6
76
0.79
0.16
1.8
2.1
—
—
—
0
0
17
192
0.88
0.15
1.3
1.3
—
—
—
0
0
138
1342
1.05
0.13
13.6
9.2
1.3
1.2
inr
0.47
36
379
11
95
1.16
0.11
2.5
3.3
—
—
—
0
0
12
106
1.14
0.10
1.2
1.2
—
—
—
0
0
30
318
0.94
0.08
1.6
1.6
—
—
—
0
0
6
57
1.05
0.08
1.2
1.2
58.9
18.6
u/l
—
6
49
25
235
1.07
0.07
3.1
4.2
0.0
0.1
%
—
6
64
12
108
1.11
0.07
17.5
10.8
—
—
—
0
0
20
213
0.94
0.06
2.5
4.4
—
—
—
0
0
161
1589
1.02
0.06
4.7
3.9
0.0
0.0
estimate
0.50
27
280
19
178
1.07
0.06
1.2
1.3
—
—
—
0
0
10
110
0.91
0.05
1.0
1.1
—
—
—
0
0
73
745
0.97
0.04
4.1
3.9
—
—
—
0
0
24
229
1.05
0.04
1.1
1.3
—
—
—
0
0
27
261
1.04
0.02
1.6
1.5
—
—
—
0
0
14
132
1.06
0.02
3.1
4.3
—
—
—
0
0
84
849
0.99
0.01
4.5
3.4
—
—
—
0
0
12
126
0.95
0.00
2.5
4.1
1.2
1.3
mmol/l
0.35
12
121
29
284
1.02
0.00
4.6
3.4
—
—
—
0
0
158
1576
1.00
0.00
5.9
5.2
0.0
0.0
estimate
0.00
27
286
0
6
0.00
0.00
0.0
1.5
—
40.0
—
0
6
0
8
0.00
0.00
0.0
17.5
—
1562.8
—
0
8
0
6
0.00
0.00
0.0
4.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.9
—
1.2
—
0
9
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
12.9
—
778.3
—
0
8
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
9
94
0.96
0.00
3.8
5.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
19.5
—
0
5
5
53
0.94
0.00
3.0
3.0
3.5
4.7
e9/l
—
5
53
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
3.6
—
—
—
0
0
5
49
1.02
0.00
2.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
5
55
0.91
0.00
3.2
3.4
60.2
59.8
%
—
5
55
0
5
0.00
0.00
0.0
7.2
—
—
—
0
0
7
76
0.92
0.00
7.7
2.8
7.4
7.4
ph
—
7
60
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_BENIGN_PARATHYROID and mortality.

Females

Parameter HR [95% CI] p-value
CD2_BENIGN_PARATHYROID 1.159 [1.0, 1.35] 0.058
Birth year 0.995 [0.99, 1.0] 0.266

During the follow-up period (1.1.1998 — 31.12.2019), 274 out of 1306 females with CD2_BENIGN_PARATHYROID died.

Males

Parameter HR [95% CI] p-value
CD2_BENIGN_PARATHYROID 1.321 [1.02, 1.71] 0.035
Birth year 0.989 [0.98, 1.0] 0.021

During the follow-up period (1.1.1998 — 31.12.2019), 101 out of 462 males with CD2_BENIGN_PARATHYROID died.

Mortality risk

Mortality risk for people of age

years, who have CD2_BENIGN_PARATHYROID.

N-year risk Females Males
1 0.131% 0.225%
5 0.641% 1.462%
10 1.589% 3.921%
15 3.173% 7.784%
20 5.666% 13.282%

Relationships between endpoints

↥

Index endpoint: CD2_BENIGN_PARATHYROID – Benign neoplasm: Parathyroid gland

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data